Ibrutinib Bests Chlorambucil in Elderly Patients with Treatment-Naïve CLL/SLL
Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Paul Barr, MD, a hematologist oncologist at the University of Rochester Medical Center, discusses the results of the RESONATE-2 (NCT01722487), which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
According to Barr, ibrutinib continues to show superior overall survival and progression-free survival (PFS) over chlorambucil. At 6.5 years, the PFS for the ibrutinib group was 61%. A similar benefit was also seen in patients who had high-risk disease, including those who were IGHV-unmutated.
In terms of response rate, the rate of complete remission (CR) with ibrutinib continues to rise, according to Barr. The CR rate is at 34%. Additionally, no new safety signals were noted.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL
April 1st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.
Read More
